Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $8.05.

Several analysts have recently issued reports on the stock. Royal Bank of Canada reduced their price target on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 27th. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating on the stock in a research report on Thursday, February 27th. Evercore ISI cut shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research report on Wednesday, April 9th. Piper Sandler reduced their price target on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 11th. Finally, KeyCorp reduced their target price on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th.

Insider Buying and Selling

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the transaction, the chief operating officer now owns 216,250 shares of the company's stock, valued at $977,450. This represents a 7.25 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,588 shares of company stock worth $225,906. Corporate insiders own 2.50% of the company's stock.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently made changes to their positions in HCAT. State Street Corp boosted its stake in shares of Health Catalyst by 2.5% during the third quarter. State Street Corp now owns 1,163,754 shares of the company's stock worth $9,473,000 after buying an additional 28,251 shares during the period. Geode Capital Management LLC boosted its stake in shares of Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company's stock worth $11,749,000 after buying an additional 66,896 shares during the period. Franklin Resources Inc. boosted its stake in shares of Health Catalyst by 5.8% during the third quarter. Franklin Resources Inc. now owns 104,141 shares of the company's stock worth $857,000 after buying an additional 5,687 shares during the period. Avanza Fonder AB acquired a new stake in shares of Health Catalyst during the fourth quarter worth about $184,000. Finally, SG Americas Securities LLC boosted its stake in shares of Health Catalyst by 21.7% during the fourth quarter. SG Americas Securities LLC now owns 27,382 shares of the company's stock worth $194,000 after buying an additional 4,874 shares during the period. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Stock Up 0.2 %

Shares of HCAT traded up $0.01 during mid-day trading on Thursday, hitting $4.07. 517,094 shares of the company's stock were exchanged, compared to its average volume of 610,518. The company has a market cap of $285.76 million, a price-to-earnings ratio of -3.01 and a beta of 1.43. Health Catalyst has a fifty-two week low of $3.56 and a fifty-two week high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock's 50-day moving average is $4.25 and its 200-day moving average is $6.17.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.